CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

NDA FilingAxpaxliPositive
AI Analysis

Summary

RBC Capital Markets reports that Ocular Therapeutix's NDA plans for Axpaxli in wet age-related macular degeneration remain on track. No specific timeline or outcome details were provided in the analyst commentary.

Importance:5/10
Sentiment:
0.30
NDAAxpaxliwet AMDregulatoryRBC Capital
Related Companies

Read the original article

Published by yahoo_finance on August 4, 2026 3:59 PM

Read Original